Clinical Trial Detail

NCT ID NCT02400385
Title A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors California Pacific Medical Center Research Institute
Indications

melanoma

Therapies

Nivolumab + Sunitinib

Age Groups: adult

Additional content available in CKB BOOST